9th Antigen-Specific Immune Tolerance Summit

Uniting 100+ leaders from cutting-edge biotechs to global pharma, this summit delivers comprehensive insight across antigen selection, biomarker strategy, B-cell and cellular tolerance mechanisms, delivery platforms, and clinical trial execution.

The 2026 agenda spotlights late-stage data from Topas, Diamyd, and COUR; novel mRNA- LNP approaches from Moderna; integrated nanotherapeutics; and next-generation Treg and tolerance-restoring strategies. Key sessions explore central versus peripheral tolerance, and how gene and cell therapy are redefining therapeutic durability and safety.

Now in its ninth year, the 9th Antigen-Specific Immune Tolerance Summit remains the only end-to-end meeting dedicated to advancing antigen-specific immune tolerance. Join Pfizer, Moderna, AbbVie, Diamyd, COUR, and others as the field transitions from discovery and preclinical efforts to real-world clinical impact. Seize the opportunity to and play a central role in rewriting these transformative therapeutics


URLs:
Website: https://go.evvnt.com/3346914-0?pid=2874
Brochure: https://go.evvnt.com/3346914-3?pid=2874

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Prices:
Industry Pricing - Conference + Workshop Day: USD 4397.00,
Industry Pricing - Conference Only: USD 3099.00,
Academic Pricing - Conference + Workshop Day: USD 3797.00,
Academic Pricing - Conference Only: USD 2699.00,
Vendor Pricing - Conference + Workshop Day: USD 5297.00,
Vendor Pricing - Conference Only: USD 3799.00

Speakers: Jason Noon, Associate Director, Head, Research and Immune Cell Depletion Group, AbbVie, David Easterhoff, Director, Autoimmunity, Moderna, Aaron Winkler, Senior Scientific Director, Immune Tolerance Lead and Inflammation, Immunology, Pfizer, Bruna Barneda, Chief Operating Officer, Ahead Therapeutics, Sara Prickett, Chief Scientific Officer, Aravax, Bill Enright, Chief Executive Officer, Barinthus Biotherapeutics , Charlotte Fribert, Chief Executive Officer, Bonsai Biotherapeutics, Adam Elhofy, Vice President and Research and Collaborations, COUR Pharma, Anton Lindqvist, Chief Scientific Officer, Diamyd Medical, Heather Denroche, Director, Preclinical Development, Integrated Nanotherapeutics , Agnete Brunsvik, Fredriksen Chief Business Officer, Nykode Therapeutics, Michael Engsig, Chief Executive Officer, Nykode Therapeutics, Peter Strumph, Chief Executive Officer, Parvus Therapeutics, Brian Freed, Chief Scientific Officer, RheumaGen, Poh Yeh-Chuin, Vice President and Head, Technical Operations, Tolerance Bio, Cristina de Min, Chief Medical Officer, Topas Therapeutics, Andrew Ferretti, Director, Technology and Platform Discovery, Tscan Therapeutics, John Kulman, Chief Scientific Officer, Zag Bio, José Carballido, University Lecturer, University of Basel